ChromaVision Enters Joint Development and Marketing Agreement with DAKO for Breast Cancer Test.SAN JUAN CAPISTRANO San Juan Capistrano (săn wän kăpĭsträ`nō), city (1990 pop. 26,183), Orange co., S Calif.; inc. 1961. San Juan Capistrano has some manufactures, including aircraft parts, medical apparatus, and boats, but the economy is , Calif.--(BW HealthWire)--Oct. 19, 1998-- Goal is to Enhance Objectivity in Selecting Women for Herceptin(R) Therapy ChromaVision Medical Systems Inc. (Nasdaq NM: CVSN), a leading cellular imaging diagnostics company, Monday announced that it has entered into a domestic co-development and cooperative sales and marketing agreement with DAKO Corp., an international diagnostics, reagent reagent /re·a·gent/ (re-a´jent) a substance used to produce a chemical reaction so as to detect, measure, produce, etc., other substances. re·a·gent n. and systems manufacturing firm. Under the agreement, the two firms will co-market the ChromaVision Automated Cellular Imaging System (ACIS(TM)) in combination with DAKO's HercepTest(R) kit in the United States United States, officially United States of America, republic (2005 est. pop. 295,734,000), 3,539,227 sq mi (9,166,598 sq km), North America. The United States is the world's third largest country in population and the fourth largest country in area. as an integrated HER2 protein expression system for the guidance of breast cancer therapy. Market availability for the system is anticipated in the first quarter of 1999, and ChromaVision estimates that the total available U.S. market under the agreement is approximately $33 million annually. Approximately 30 percent of breast cancer patients have a particularly aggressive cancer identified by the elevated expression of a protein called HER2. The HER2 protein is important for normal cell division; however, if patients overexpress this protein, their cancer can spread very rapidly. The drug Herceptin(R), developed by Genentech, has recently been approved by the FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. to treat metastatic Metastatic The term used to describe a secondary cancer, or one that has spread from one area of the body to another. Mentioned in: Coagulation Disorders metastatic pertaining to or of the nature of a metastasis. breast cancer, and the DAKO HercepTest kit has been FDA approved to measure the overexpression of the HER2 protein in a patient's tumor. In FDA statements related to the use of HercepTest, the advisory panel noted that the manual method of visually assessing HER2 expression may make it difficult to distinguish women who may benefit from Herceptin. The ChromaVision ACIS, in conjunction with the DAKO test, can offer pathologists a tool to quantify the amount of the HER2 protein expression in an objective and reproducible manner -- replacing subjective interpretation. According to according to prep. 1. As stated or indicated by; on the authority of: according to historians. 2. In keeping with: according to instructions. 3. Dr. Michael Press, a leading cancer researcher at the Kenneth Norris, Jr. Comprehensive Cancer Center at the University of Southern California The U.S. News & World Report ranked USC 27th among all universities in the United States in its 2008 ranking of "America's Best Colleges", also designating it as one of the "most selective universities" for admitting 8,634 of the almost 34,000 who applied for freshman admission , "An issue related to current tests for HER2 expression is the subjective nature of distinguishing low HER2 expression from overexpression. The ChromaVision ACIS will provide an objective and quantitative approach intended to eliminate this observer bias." DAKO Corp. President Viggo Harboe commented, "The development and marketing collaboration between ChromaVision and DAKO will greatly enhance the objective interpretation of HER2 protein expression. It is our collective goal that the integration of the DAKO HercepTest and ChromaVision ACIS will significantly contribute to the optimal treatment of metastatic breast cancer patients." About ChromaVision Medical Systems ChromaVision Medical Systems manufactures and markets an advanced cellular imaging system designed to advance the detection, diagnosis, and treatment of cellular disease. The Automated Cellular Imaging System (ACIS) combines a proprietary, color-based imaging technology with automated microscopy to bring unprecedented sensitivity, accuracy and reproducibility to cancer, infectious disease Infectious disease A pathological condition spread among biological species. Infectious diseases, although varied in their effects, are always associated with viruses, bacteria, fungi, protozoa, multicellular parasites and aberrant proteins known as prions. and genetic cell-based diagnostics. ChromaVision currently markets its products to research centers, university medical centers and commercial laboratories throughout the world. About DAKO DAKO is a leader in immunohistochemical testing for diagnosis of tumors and develops, manufactures and sells diagnostic products and systems for immunohistochemistry, molecular pathology Molecular pathology is an emerging discipline within pathology which is focused on the use of nucleic acid-based techniques such as DNA sequencing, fluorescent in-situ hybridization, reverse-transcriptase polymerase chain reaction, and nucleic acid microarrays for specialised studies of , flow cytometry flow cytometry (flōˑ sī·t  ˑ·m , clinical immunochemistry ImmunochemistryA discipline concerned both with the structure of antibody (immunoglobulin) molecules and with their ability to bind an apparently limitless number of diverse chemical structures (antigens); with the structure, organization, and rearrangement and microbiology. The statements contained herein regarding ChromaVision Medical Systems Inc. contain forward-looking statements that involve risks and uncertainty. Future events and the company's actual results could differ materially from the results reflected in these forward-looking statements. Factors that might cause such a difference include, but are not limited to, uncertainty of success in developing any new diagnostic test, failure to obtain FDA clearance or approval for particular applications and dependence on third parties for clinical testing. ACIS is a trademark of ChromaVision Medical Systems Inc. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion